Prostate Cancer

Advanced prostate cancer treatment includes androgen receptor pathway inhibitors, PARP inhibitors for HRR-mutated tumors, and lutetium PSMA-617 radioligand therapy for metastatic CRPC. Combination approaches are defining the current standard of care.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Prostate Cancer

• Enzalutamide (Xtandi) — Hormonal Agent
• Apalutamide (Erleada) — Hormonal Agent
• Darolutamide (Nubeqa) — Hormonal Agent
• Abiraterone Acetate (Zytiga) — Hormonal Agent
• Olaparib (Lynparza) — PARP Inhibitor
• Rucaparib (Rubraca) — PARP Inhibitor
• Lutetium (177Lu) vipivotide tetraxetan (Pluvicto) — Other
• Cabazitaxel (Jevtana) — Taxane
• Docetaxel (Taxotere) — Taxane